Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM.

Neurogenetics. 2009 Feb;10(1):13-7. doi: 10.1007/s10048-008-0150-4. Epub 2008 Sep 24.

2.

Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM; Alzheimer's Disease Neuroimaging Initiative, Goate AM.

J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.

3.

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Kauwe JS, Goate AM, Cruchaga C.

Acta Neuropathol. 2017 May;133(5):839-856. doi: 10.1007/s00401-017-1685-y. Epub 2017 Feb 28.

PMID:
28247064
4.

Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer's Disease.

Wang C, Tan L, Wang HF, Yu WJ, Liu Y, Jiang T, Tan MS, Hao XK, Zhang DQ, Yu JT; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;46(2):491-5. doi: 10.3233/JAD-150110.

PMID:
26402410
5.

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050-4. doi: 10.1073/pnas.0801227105. Epub 2008 Jun 9.

6.

The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.

Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L.

Arch Gen Psychiatry. 2011 Feb;68(2):207-13. doi: 10.1001/archgenpsychiatry.2010.196.

PMID:
21300948
7.

Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's.

Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ.

Biol Psychiatry. 2010 Nov 15;68(10):913-21. doi: 10.1016/j.biopsych.2010.07.011.

8.

Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.

Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM.

Ann Neurol. 2007 May;61(5):446-53.

PMID:
17366635
9.

Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease.

Louwersheimer E, Ramirez A, Cruchaga C, Becker T, Kornhuber J, Peters O, Heilmann S, Wiltfang J, Jessen F, Visser PJ, Scheltens P, Pijnenburg YA, Teunissen CE, Barkhof F, van Swieten JC, Holstege H, Van der Flier WM; Alzheimer's Disease Neuroimaging Initiative and Dementia Competence Network.

Neurobiol Aging. 2015 Mar;36(3):1605.e13-20. doi: 10.1016/j.neurobiolaging.2014.12.007. Epub 2014 Dec 11.

PMID:
25659857
10.

Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM.

Neurobiol Aging. 2014 Feb;35(2):357-64. doi: 10.1016/j.neurobiolaging.2013.07.027. Epub 2013 Sep 4.

11.

Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.

Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajärvi T, Natunen T, Kurkinen KM, Huovinen J, Mäkinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimäki T, Remes AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M.

J Alzheimers Dis. 2015;43(2):565-73. doi: 10.3233/JAD-140777.

PMID:
25096612
12.

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.

Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778.

PMID:
25790831
13.

A multi-center study of ACE and the risk of late-onset Alzheimer's disease.

Belbin O, Brown K, Shi H, Medway C, Abraham R, Passmore P, Mann D, Smith AD, Holmes C, McGuinness B, Craig D, Warden D, Heun R, Kölsch H, Love S, Kalsheker N, Williams J, Owen MJ, Carrasquillo M, Younkin S, Morgan K, Kehoe PG.

J Alzheimers Dis. 2011;24(3):587-97. doi: 10.3233/JAD-2011-101914.

14.

ABCB1 genotype and CSF beta-amyloid in Alzheimer disease.

Kohen R, Shofer JB, Korvatska O, Petrie EC, Wang LY, Schellenberg GD, Peskind ER, Wilkinson CW.

J Geriatr Psychiatry Neurol. 2011 Jun;24(2):63-6. doi: 10.1177/0891988711402325. Epub 2011 Apr 8.

15.

Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?

Travassos M, Santana I, Baldeiras I, Tsolaki M, Gkatzima O, Sermin G, Yener GG, Simonsen A, Hasselbalch SG, Kapaki E, Mara B, Cunha RA, Agostinho P, Blennow K, Zetterberg H, Mendes VM, Manadas B, de Mendon A.

J Alzheimers Dis. 2015;47(4):1069-78. doi: 10.3233/JAD-150374.

PMID:
26401784
16.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
17.

Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.

Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H.

Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):720-6. doi: 10.1002/ajmg.b.30668.

PMID:
18163432
18.

Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD.

Lebedeva E, Stingl JC, Thal DR, Ghebremedhin E, Strauss J, Özer E, Bertram L, von Einem B, Tumani H, Otto M, Riepe MW, Högel J, Ludolph AC, von Arnim CA.

Neurobiol Aging. 2012 Jan;33(1):201.e9-18. doi: 10.1016/j.neurobiolaging.2010.07.017. Epub 2010 Sep 18.

PMID:
20850903
19.

The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.

Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM.

Curr Alzheimer Res. 2010 Aug;7(5):470-6.

PMID:
20043812
20.

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F.

Lancet Neurol. 2012 Dec;11(12):1048-56. doi: 10.1016/S1474-4422(12)70228-4. Epub 2012 Nov 6.

Supplemental Content

Support Center